These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 10834038)

  • 1. Interpreting the results of small trials.
    Molnar F; Man-Son-Hing M; Byszewski A; Azid N
    CMAJ; 2000 May; 162(10):1401. PubMed ID: 10834038
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
    Mehraban D; Esfahani F
    J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
    [No Abstract]   [Full Text] [Related]  

  • 3. [Failures in sample size calculation in randomized trial: mandatory and mystical].
    Schulz KF; Grimes DA
    Z Arztl Fortbild Qualitatssich; 2006; 100(2):129-35. PubMed ID: 16686447
    [No Abstract]   [Full Text] [Related]  

  • 4. Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials.
    Diehr P; Chen L; Patrick D; Feng Z; Yasui Y
    Contemp Clin Trials; 2005 Feb; 26(1):45-58. PubMed ID: 15837452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining a proper sample size.
    Fogel J
    Fam Pract Manag; 2004 Oct; 11(9):14; author reply 14. PubMed ID: 15552243
    [No Abstract]   [Full Text] [Related]  

  • 6. [Limitations of clinical trials].
    Collet JP
    Rev Prat; 2000 Apr; 50(8):833-7. PubMed ID: 10874859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations in determining sample size for pilot studies.
    Hertzog MA
    Res Nurs Health; 2008 Apr; 31(2):180-91. PubMed ID: 18183564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trend in randomized controlled trials.
    Băicuş C
    Rom J Intern Med; 2003; 41(3):329-32. PubMed ID: 15526517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating clinical literature.
    Strite S; Stuart ME
    Fam Pract Manag; 2004 Oct; 11(9):14, 16; author reply 16. PubMed ID: 15552244
    [No Abstract]   [Full Text] [Related]  

  • 10. Sample size calculations for 3-level cluster randomized trials.
    Teerenstra S; Moerbeek M; van Achterberg T; Pelzer BJ; Borm GF
    Clin Trials; 2008; 5(5):486-95. PubMed ID: 18827041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers.
    Glynn RJ; Brookhart MA; Stedman M; Avorn J; Solomon DH
    Med Care; 2007 Oct; 45(10 Supl 2):S38-43. PubMed ID: 17909381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite outcomes in randomized clinical trials: arguments for and against.
    Ross S
    Am J Obstet Gynecol; 2007 Feb; 196(2):119.e1-6. PubMed ID: 17306647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials.
    Kjaergard LL; Gluud C
    Am J Gastroenterol; 2002 Nov; 97(11):2708-13. PubMed ID: 12425537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we cautious enough when we interpret results of randomized but underpowered comparisons?
    Paesmans M; Bleiberg H
    J Clin Oncol; 2006 Apr; 24(12):1964-5. PubMed ID: 16622279
    [No Abstract]   [Full Text] [Related]  

  • 16. Basics of methodologic analysis of therapeutic trials. Part II: Importance of the results.
    Soares I; Carneiro AV
    Rev Port Cardiol; 2002 May; 21(5):613-26. PubMed ID: 12174523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of community-intervention trials via generalized linear mixed models.
    Yasui Y; Feng Z; Diehr P; McLerran D; Beresford SA; McCulloch CE
    Biometrics; 2004 Dec; 60(4):1043-52. PubMed ID: 15606425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety reporting in randomized clinical trials - a need for improvement.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(2):209-10. PubMed ID: 19583556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On sample size calculation for 2x2 fixed-effect ANOVA when variances are unknown and possibly unequal.
    Guo JH; Luh WM
    Br J Math Stat Psychol; 2009 May; 62(Pt 2):417-25. PubMed ID: 18559139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.